Adalimumab in psoriatic arthritis: 24-week results of a phase III study

被引：0
|
作者：
Mease, P
Gladman, D
Ritchlin, C
Weinberg, M
机构：
[1] Univ Washington, Sch Med, Seattle, WA USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Rochester, Rochester, NY USA
[4] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2005年 / 52卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：P2 / P2
页数：1
相关论文
共 50 条
  • [1] Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SED
    Choy, EHS
    Perdok, RJ
    Weinberg, TA
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4097 - 4097
  • [2] Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
    Mease, P.
    Gottlieb, A. B.
    van der Heijde, D.
    FitzGerald, Oliver
    Johnsen, A.
    Nys, M.
    Banerjee, S.
    Gladman, D.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [3] ABATACEPT IN THE TREATMENT OF ACTIVE PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM A PHASE III STUDY
    Mease, P.
    Gottlieb, A.
    Van der Heijde, D.
    Fitzgerald, O.
    Johnsen, A.
    Nys, M.
    Banerjee, S.
    Xinos, C.
    Gladman, D.
    INTERNAL MEDICINE JOURNAL, 2017, 47 : 23 - 23
  • [4] Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
    Mease, Philip
    Gottlieb, Alice
    van der Heijde, Desiree
    FitzGerald, Oliver
    Johnsen, Alyssa
    Nys, Marleen
    Banerjee, Subhashis
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 926 - 926
  • [5] 24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)
    Mease, PJ
    Choy, EHS
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SD
    Weinberg, MA
    RHEUMATOLOGY, 2005, 44 : I3 - I3
  • [6] TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE PHASE III RANDOMISED ULTIMATE STUDY
    D'agostino, M. A.
    Conaghan, P. G.
    Gaillez, C.
    Boers, M.
    Naredo, E.
    Carron, P.
    Hanova, P.
    Cazenave, T.
    Bakewell, C.
    Duggan, A. M.
    Goyanka, P.
    Schett, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 136 - 137
  • [7] Brodalumab in psoriatic arthritis (PsA): 24-week results from the phase III AMVISON-1 and-2 trials
    McInnes, Iain
    Mease, Philip
    Hjuler, Kasper Fjellhaugen
    Raymond, Kyle
    Helliwell, Philip
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB28 - AB28
  • [8] Tocilizumab Monotherapy Compared with Adalimumab Monotherapy in Patients with Rheumatoid Arthritis: Results of a 24-Week Study.
    Kavanaugh, Arthur
    Emery, Paul
    van Vollenhoven, Ronald F.
    Dikranian, Ara H.
    Alten, Rieke
    Klearman, Micki
    Musselman, David
    Agarwal, Sunil
    Green, Jennifer
    Gabay, Cem
    ARTHRITIS AND RHEUMATISM, 2012, 64 (10): : S333 - S334
  • [9] TOWARDS DEVELOPMENT OF AN ULTRASOUND ENTHESITIS SCORE IN PSORIATIC ARTHRITIS: 24-WEEK RESULTS FROM THE ULTIMATE STUDY
    D'Agostino, M. A.
    Conaghan, P. G.
    Gaillez, C.
    Boers, M.
    Naredo, E.
    Carron, P.
    Hanova, P.
    Cazenave, T.
    Bakewell, C.
    Duggan, A. M.
    Goyanka, P.
    Schett, G.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2021, 39 (05) : 1160 - 1161
  • [10] Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study
    Gladman, D.
    Fleischmann, R.
    Coteur, G.
    Woltering, F.
    Mease, P. J.
    ARTHRITIS CARE & RESEARCH, 2014, 66 (07) : 1085 - 1092
12345